Supplementary Information

# Synthesis of a cross-chain bridging cryptand

Takafumi Yashima, Ryoga Hori, Taisei Maruyama, Kohta Nakashima, Hiroki Fujihara, Masaya Naito, Shinobu Miyagawa and Yuji Tokunaga

# TOC

1.	Experimental	1
2.	Figure S1. Interconversion of the cross-chain bridging cryptand between both enan	ntiomers.
		17
3.	Figure S2. GPC analysis of the linking reaction of the crown ether 3a.	18
4.	Figure S3. GPC analysis of the linking reaction of the crown ether 3b.	19
5.	Figure S4. <sup>1</sup> H NMR spectrum of the cryptand 1c.	20
6.	Figure S5. <sup>13</sup> C NMR spectra of the cryptand 1c.	21
7.	Figure S6. COSY spectrum of the cryptand 1c.	22
8.	Figure S7. ROESY spectrum of the cryptand 1c.	23
9.	Figure S8. HSQC spectrum of the cryptand 1c.	24
10.	Figure S9. HMBC spectrum of the cryptand 1c.	25
11.	Figure S10. Mass spectrum of the cryptand 1c.	27
12.	Figure S11. <sup>1</sup> H NMR spectrum of the cryptand 6a.	28
13.	Figure S12. COSY spectrum of the linear cryptand 6a.	29
14.	Figure S13. ROESY spectrum of the linear cryptand 6a.	30
15.	Figure S14. Mass spectrum of the cryptand 6a.	31
16.	Figure S15. <sup>1</sup> H NMR spectrum of the cryptand 6b.	32
17.	Figure S16. COSY spectrum of the linear cryptand 6b.	33
18.	Figure S17. ROESY spectrum of the linear cryptand 6b.	34
19.	Figure S18. Mass spectrum of the cryptand 6b.	35
20.	Figure S19. Detailed steps of the triple linking reaction of the tosylate 4 and ethyl g	gallate from the
	minor phenoxide of ethyl gallate.	36
21.	Figure S20. Chiral HPLC analysis of the cryptand 1c.	38
22.	Figure S21. X-ray crystal structure of the racemic cryptand 1a.	39
23.	Table S1. Crystal data of the racemic cryptand 1a.	40
24.	Figure. NMR spectra of the compounds.	41

# Experimental

#### **Materials and General Methods**

The compounds 7 and 9a were prepared according to literature procedures.<sup>S1</sup> DMF and CH<sub>2</sub>Cl<sub>2</sub> were dried over 4 Å molecular sieves. Other solvents and commercially available chemicals were used as received. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded using JEOL ECX-500II and ECA-600II spectrometers, with tetramethylsilane (0 ppm) and C<sub>6</sub>HD<sub>5</sub> (7.15 ppm) for <sup>1</sup>H NMR and with CDCl<sub>3</sub> (71.0 ppm) and  $C_6D_6$  (128.0 ppm) for <sup>13</sup>C NMR as the internal standard. Mass spectra were recorded using JEOL JMS-700T (FAB) and JMS-S3000 (MALDI) spectrometers. Infrared spectra were recorded using a Shimadzu FTIR-8600PC spectrometer. All reactions were performed under a positive atmosphere of dry N2 expect for hydrogenation (conversion of mixtures of compounds 10 and 11 to compounds 3 and 12). All solvents were removed through rotary evaporation under reduced pressure. Silica gel column chromatography was performed using Kanto Chemical silica gel 60N. Thin layer chromatography was performed using Merck Kieselgel 60PF254. For reactions that require heating used an oil bath as the heat source. HPLC was performed using a JASCO LC-NetII/ADC and a PU-2080 plus detector, with GL Siences Inertsil ODS-3 5  $\mu$ m column (10 × 250 mm) for separation of isomers 1 and 6 and a Shimadzu SDD-M20A detector, with DAICEL CHIRALPAK IG-3 for analysis of compound 1c. GPC was performed using a Japan Analytical Industry LC-5060 apparatus and JAIGEL (2H and 2.5H).

#### References

S1. H. Fujihara, M. Naito, T. Yashima, Y. Okada, N. Kobayashi, S. Miyagawa, H. Takaya, Y. Tokunaga, *Org. Lett.*, 2023, **25**, 8959–8964.

#### **XRD** structure determination

A crystal suitable for XRD was analyzed using a Rigaku R-AXIS RAPID diffractometer and graphitemonochromated Mo<sub>Ka</sub> radiation ( $\lambda = 0.71075$  Å). The structure of **1a** was solved using direct methods and refined by applying the full-matrix least-squares method. In subsequent refinement, the function  $\Sigma\omega(F_o^2 - F_c^2)^2$  was minimized, where  $F_o$  and  $F_c$  are the observed and calculated structure factor amplitudes, respectively. The positions of non-hydrogen atoms were determined from difference Fourier electron density maps and were refined anisotropically. All calculations were performed using the Rigaku CrystalStructure crystallographic software package; illustrations were generated in the ORTEP style. Details of the structural determinations are provided in Figures 6, S21 and Table S1. CCDC 2392777 contains the supplementary crystallographic data for this paper.



#### Synthesis of cryptand 1a.

A mixture of crown ethers 10a and 11a



A suspension of dichloride **9a** (2.61 g, 4.43 mmol), gallate **7** (1.28 g, 4.43 mmol),  $Cs_2CO_3$  (4.33 g, 13.3 mmol), and CsI (345 mg, 1.33 mmol) in DMF (90 mL) was stirred at 100 °C for 60 h. After evaporation of the solvent, 10% HCl (aq.) was added to the residue and the aqueous phase was extracted with AcOEt. The organic extract was washed with water, dried (MgSO<sub>4</sub>), and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; toluene/AcOEt, 2:1) to afford a white solid (2.26 g, 63%), as a 1:1 mixture of crown ethers **10a** and **11a**.

IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 2931, 2873, 1713, 1588, 1504, 1428, 1366, 1231, 1123, 1032, 763.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.48–7.42 (m, 4H), 7.40–7.34 (m, 6H), 7.31 (br t, *J* = 7.4 Hz, 2H), 7.27 (br s, 2H), 5.13 (s, 4H), 4.34 (q, *J* = 7.0 Hz, 4H), 4.27–4.17 (m, 8H), 3.95–3.88 (m, 4H), 3.86–3.80 (m, 6H), 3.78–3.72 (m, 6H), 1.37 (t, *J* = 7.0 Hz, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 166.1, 152.5, 152.4, 152.2, 152.1, 142.5, 142.4, 136.8, 128.5, 127.9, 127.4, 127.3, 125.4, 125.3, 109.1, 108.3, 72.55, 72.45, 71.2, 71.1, 70.7, 70.6, 69.7, 69.6, 69.0, 61.1, 14.4. Six aliphatic/carbonyl and seven aromatic carbon signals were overlapping/missing.
MS (FAB): *m/z* calcd for C<sub>44</sub>H<sub>53</sub>O<sub>14</sub><sup>+</sup> [M+H]<sup>+</sup>: 805.3430; found: 805.3459.

Crown ethers 3a and 12a



A suspension of a 1:1 mixture of crown ethers **10a** and **11a** (430 mg, 0.534 mmol), 10% Pd-C (121 mg) in EtOH (10 mL) and CHCl<sub>3</sub> (5 mL) was stirred for 2 d under hydrogen. After the mixture was filtered through celite, the filtrate was concentrated. The residue was purified through column chromatography (SiO<sub>2</sub>; toluene/CHCl<sub>3</sub>/AcOEt, 1:1:1) to give the crown ether **3a** as a colorless solid and (SiO<sub>2</sub>; toluene/CHCl<sub>3</sub>/AcOEt, 1:1:2) to give the crown ether **12a** as a colorless solid. Both crown ethers were washed with iPr<sub>2</sub>O to afford **3a** (136 mg, 41%) and **12a** (146 mg, 44%) as colorless solids, respectively.

Crown ether 3a



IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 3303, 2972, 2876, 1714, 1592, 1509, 1445, 1398, 1369, 1237, 1214, 1094, 1038, 957, 903, 867, 766.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.64 (s, 2H), 7.24 (br s, 2H), 7.11 (br s, 2H), 4.33 (q, J = 7.1 Hz, 4H), 4.24–4.19 (m, 4H), 4.16–4.11 (m, 4H), 3.86–3.78 (m, 12H), 3.78–3.72 (m, 4H), 1.37 (t, J = 7.1 Hz, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 166.3, 152.0, 150.6, 139.2, 126.4, 110.7, 105.4, 73.5, 71.9, 70.0, 69.8, 69.3, 67.6, 60.9, 14.3.

MS (FAB): m/z calcd for C<sub>30</sub>H<sub>41</sub>O<sub>14</sub><sup>+</sup> [M+H]<sup>+</sup>: 625.2491; found: 625.2520.

mp: 181–183 °C (acetone).

Crown ether 12a



IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 3407, 2980, 2873, 1714, 1593, 1508, 1445, 1364, 1342, 1237, 1215, 1098, 1034, 955, 888, 762.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.29 (d, *J* = 1.7 Hz, 2H), 7.16 (d, *J* = 1.7 Hz, 2H), 6.98 (s, 2H), 4.33 (q, *J* = 7.1 Hz, 4H), 4.26–4.18 (m, 8H), 3.85–3.78 (m, 8H), 3.77 (s, 4H), 3.69 (s, 4H), 1.37 (t, *J* = 7.1 Hz, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 166.2, 151.5, 150.0, 139.4, 126.2, 110.6, 106.8, 72.8, 71.2, 70.8, 70.4, 69.6, 68.7, 61.0, 14.3.

MS (FAB): *m*/*z* calcd for C<sub>30</sub>H<sub>41</sub>O<sub>14</sub><sup>+</sup> [M+H]<sup>+</sup>: 625.2491; found: 625.2498. mp: 192–194 °C (CHCl<sub>3</sub>).

Cryptand 1a



Using Cs<sub>2</sub>CO<sub>3</sub>

A suspension of the crown ether **3a** (80.3 mg, 0.129 mmol), tri(ethylene glycol) ditosylate **13a** (58.9 mg, 0.129 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (126 mg, 0.386 mmol) in DMF (16 mL) was heated at 95 °C for 43 h. After evaporation of the solvent, 10% HCl (aq.) was added to the residue and the aqueous phase was

extracted with AcOEt. The organic extract was washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by GPC (eluent CHCl<sub>3</sub>) to afford a white solid (27.3 mg, 34%).

# Using K<sub>2</sub>CO<sub>3</sub>

The cryptand **1a** (56.0 mg, 59%) was synthesized from the crown ether **3a** (80.1 mg, 0.128 mmol) and  $K_2CO_3$  (53.2 mg, 0.384 mmol) instead of  $Cs_2CO_3$ , using the procedure described above, as a white solid.

# Using Na<sub>2</sub>CO<sub>3</sub>

The cryptand **1a** (19.0 mg, 20%) was synthesized from the crown ether **3a** (79.4 mg, 0.127 mmol) and Na<sub>2</sub>CO<sub>3</sub> (40.6 mg, 0.383 mmol) instead of Cs<sub>2</sub>CO<sub>3</sub>, using the procedure described above, as a white solid.

Synthesis of cryptand 1b.

Compound 9b



A suspension of ethyl gallate (7) (9.40 g, 32.7 mmol), tetra(ethylene glycol) monotosylate **8b** (28.4 g, 81.6 mmol), and  $K_2CO_3$  (11.3 g, 81.6 mmol) in acetonitrile (111 mL) and DMF (38 mL) was heated at 95 °C for 17 h. After evaporation of the solvent, 10% HCl (aq.) and water were added to the residue and the aqueous phase was extracted with AcOEt. The organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified through column chromatography (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH, 20:1) to a colorless oil (16.13 g, 77%).

IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 3443, 2873, 1713, 1589, 1502, 1430, 1368, 1333, 1236, 1213, 1120, 1030, 947, 766.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.48–7.44 (m, 2H), 7.41–7.36 (m, 2H), 7.37 (d, *J* = 2.1 Hz, 1H), 7.34– 7.30 (m, 1H), 7.31 (d, *J* = 2.1 Hz, 1H), 5.14 (s, 2H), 4.35 (q, *J* = 7.0 Hz, 2H), 4.26–4.20 (m, 4H), 3.90– 3.87 (m, 2H), 3.81–3.78 (m, 2H), 3.76–3.73 (m, 2H), 3.73–3.65 (m, 12H), 3.65–3.62 (m, 2H), 3.65– 3.56 (m, 8H), 1.38 (t, *J* = 7.0 Hz, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 166.0, 152.2, 152.1, 142.4, 136.7, 128.4, 127.9, 127.4, 125.3, 109.0, 108.8, 72.5, 71.1, 70.7, 70.53, 70.47, 70.4, 70.24, 70.18, 69.5, 68.7, 61.6, 61.0, 14.3. Six aliphatic carbon signals were overlapping/missing.

MS (FAB): m/z calcd for C<sub>32</sub>H<sub>49</sub>O<sub>13</sub><sup>+</sup> [M+H]<sup>+</sup>: 641.3168; found: 641.3188.

#### Compound 9c



Et<sub>3</sub>N (0.55 mL, 3.95 mmol) was added to a solution of diol **9b** (1.00 g, 1.56 mmol), *p*-toluenesulfonyl chloride (0.685 g, 3.59 mmol), and 4-dimethylaminopyridine (DMAP, 19.5 mg, 0.160 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at 0 °C. After stirring at room temperature for 13 h, the mixture concentrated. Water was added to the residue, the aqueous phase was extracted with AcOEt. Combined organic phase was washed with sat. NaCl (aq.), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified through column chromatography (SiO<sub>2</sub>; hexane/ethyl acetate, 1:3) to a colorless oil (1.16 g, 78%). IR (KBr,  $\nu_{max}$ ) cm<sup>-1</sup>: 2872, 1714, 1430, 1358, 1333, 1212, 1177, 1112, 1019, 923, 816, 769. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.80–7.76 (m, 4H), 7.47–7.44 (m, 2H), 7.40–7.35 (m, 3H), 7.35–7.29

(m, 6H), 5.13 (s, 2H), 4.34 (q, *J* = 7.2 Hz, 2H), 4.24–4.18 (m, 4H), 4.16–4.11 (m, 4H), 3.88–3.85 (m, 2H), 3.79–3.76 (m, 2H), 3.72–3.61 (m, 10H), 3.59–3.57 (m, 4H), 3.55–3.51 (m, 6H), 2.431 (s, 3H), 2.427 (s, 3H), 1.38 (t, *J* = 7.2 Hz, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 166.0, 152.2, 152.1, 144.7, 142.4, 136.7, 132.8, 129.7, 128.4, 127.9, 127.4, 125.3, 109.0, 108.8, 72.4, 71.1, 70.7, 70.63, 70.59, 70.51, 70.44, 70.37, 69.5, 69.2, 68.7, 68.6, 68.5, 61.0, 21.6, 14.3. Five aliphatic and five aromatic carbon signals were overlapping/missing.
MS (FAB): *m/z* calcd for C<sub>46</sub>H<sub>61</sub>O<sub>17</sub>S<sub>2</sub><sup>+</sup> [M+H]<sup>+</sup>: 949.3345; found: 949.3351.



A suspension of ditosylate **9c** (1.99 g, 2.09 mmol), ethyl gallate (7) (0.618 g, 2.14 mmol), and cesium carbonate (2.14 g, 6.56 mmol) in DMF (100 mL) was stirred at 100 °C for 72 h. After evaporation of the solvent, dil HCl (aq.) was added to the residue and the aqueous phase was extracted with AcOEt. The organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified through column chromatography (SiO<sub>2</sub>; toluene/acetone, 4:1) to give a 1:1 mixture of crown ethers **10b** and **11b** (0.983 g, 52%) as a colorless solid.

IR (KBr,  $v_{max}$ ) cm<sup>-1</sup>: 2873, 1712, 1589, 1503, 1429, 1367, 1336, 1233, 1213, 1120, 1031, 763. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.47–7.42 (m, 4H), 7.40–7.34 (m, 6H), 7.34–7.29 (m, 2H), 7.29–7.26 (m, 2H), 5.13 (s, 4H), 4.34 (q, *J* = 7.2 Hz, 4H), 4.26–4.17 (m, 8H), 3.92–3.87 (m, 4H), 3.83–3.79 (m, 4H), 3.78–3.73 (m, 4H), 3.72–3.65 (m, 8H), 3.65–3.60 (m, 4H), 1.37 (t, *J* = 7.2 Hz, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 166.1, 152.4, 152.1, 142.5, 136.7, 128.5, 127.9, 127.4, 125.3, 109.1, 108.6, 108.5, 72.5, 71.2, 70.9, 70.71, 70.67, 70.6, 70.5, 69.6, 68.9, 61.0, 14.3. Ten aliphatic and eleven

aromatic/carbonyl carbon signals were overlapping/missing.

MS (FAB): m/z calcd for C<sub>48</sub>H<sub>61</sub>O<sub>16</sub><sup>+</sup> [M+H]<sup>+</sup>: 893.3954; found: 893.3995.

Crown ethers **3b** and **12b** 



A suspension of 1:1 mixture of the crown ethers **10b** and **11b** (0.960 g, 1.07 mmol) and 10% Pd-C (0.337 g) in EtOH/CHCl<sub>3</sub> (39 mL, 2:1) was stirred at room temperature for 23 h under hydrogen atmosphere. After filtration through celite, the filtrate was concentrated. The residue was crystalized from MeOH to give a 93:7 mixture of the crown ethers **3b** (339 mg, 44%), which was washed with EtOH to afford the crown **3b** (190 mg, 25%) as a white solid. After concentration of the above first filtrate, the residue was treated with cold iPrOH to give the crown ether **12b** (323 mg, 42%) as a white solid.

Crown ether **3b** 



IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 3423, 2929, 2872, 1698, 1592, 1507, 1445, 1370, 1349, 1229, 1102, 1044, 878, 768.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.42 (s, 2H), 7.24 (br s, 2H), 7.08 (br s, 2H), 4.32 (q, *J* = 7.2 Hz, 4H), 4.27–4.21 (m, 4H), 4.20–4.15 (m, 4H), 3.89–3.84 (m, 4H), 3.75–3.61 (m, 20H), 1.36 (t, *J* = 7.2 Hz, 6H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 166.2, 151.9, 150.6, 138.7, 126.2, 110.6, 105.9, 72.5, 70.8, 70.7, 70.5, 70.4, 69.5, 68.2, 60.9, 14.3. One aliphatic carbon signal was overlapping/missing.

MS (FAB): m/z calcd for C<sub>34</sub>H<sub>49</sub>O<sub>16</sub><sup>+</sup> [M+H]<sup>+</sup>: 713.3015; found: 713.3047.

mp: 128–129 °C (CHCl<sub>3</sub>/hexane).

Crown ether 12b



IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 3421, 3128, 2901, 2873, 1714, 1699, 1592, 1510, 1431, 1370, 1348, 1234, 1103, 1029, 768.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.53 (s, 2H), 7.29 (d, J = 1.7 Hz, 2H), 7.13 (d, J = 1.7 Hz, 2H), 4.33

(q, J = 7.0 Hz, 4H), 4.21–4.17 (m, 8H), 3.87–3.84 (m, 4H), 3.74–3.68 (s, 16H), 3.67–3.64 (s, 4H), 1.36 (t, J = 7.0 Hz, 6H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$ : 166.2, 152.0, 150.7, 139.0, 126.3, 110.8, 106.1, 72.7, 71.0, 70.80, 70.77, 70.3, 69.7, 69.6, 68.7, 61.0, 14.3. MS (FAB): m/z calcd for C<sub>34</sub>H<sub>49</sub>O<sub>16<sup>+</sup></sub> [M+H]<sup>+</sup>: 713.3015; found: 713.3001. mp: 99–100 °C (EtOH).

Cryptand 1b



Using Cs<sub>2</sub>CO<sub>3</sub>

The cryptand **1b** (60.5 mg, 62%) was synthesized from the crown ether **3b** (80.1 mg, 0.112 mmol) and tetra(ethyleneglycol) ditosylate (56.5 mg, 0.112 mmol), using the procedure for synthesis of the cryptand **1a**, as a white solid.

Using K<sub>2</sub>CO<sub>3</sub>

The cryptand **1b** (63.1 mg, 65%) was synthesized from the crown ether **3b** (80.1 mg, 0.128 mmol) and  $K_2CO_3$  (46.9 mg, 0.338 mmol) instead of  $Cs_2CO_3$ , using the procedure described above, as a white solid.

Using Na<sub>2</sub>CO<sub>3</sub>

The cryptand **1b** (37.5 mg, 38%) was synthesized from the crown ether **3b** (79.4 mg, 0.127 mmol) and Na<sub>2</sub>CO<sub>3</sub> (40.6 mg, 0.383 mmol) instead of Cs<sub>2</sub>CO<sub>3</sub>, using the procedure described above, as a white solid.

#### Synthesis of cryptand 1c.



## Cryptand 1c

# Using K<sub>2</sub>CO<sub>3</sub>

A suspension of crown **3b** (200 mg, 0.281 mmol), tri(ethylene glycol) ditosylate **13a** (128 mg, 0.280 mmol), and  $K_2CO_3$  (156 mg, 1.13 mmol) in DMF (80 mL) was stirred 3 d at 100 °C. After evaporation of the solvent, the residue was neutralized with dil. HCl (aq.). The aqueous mixture was extracted with AcOEt. Combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified through GPC to give the crude product, which was washed with iPr<sub>2</sub>O and hexane to the cryptand **1c** (118 mg, 52 %) as a white solid.

#### Using Cs<sub>2</sub>CO<sub>3</sub>

The cryptand 1c (119 mg, 52%) was synthesized from the crown ether **3b** (200 mg, 0.281 mmol) and  $Cs_2CO_3$  (367 mg, 1.13 mmol) instead of  $K_2CO_3$ , using the procedure described above, as a white solid.

IR (KBr,  $v_{max}$ ) cm<sup>-1</sup>: 2872, 1717, 1589, 1501, 1431, 1368, 1331, 1245, 1206, 1121, 1030, 940, 768. <sup>1</sup>H NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 7.554 (d, *J* = 1.7 Hz, 2H), 7.548 (d, *J* = 1.7 Hz, 2H), 4.51 (dt, *J* = 10.6 and 5.2 Hz, 2H), 4.44 (dt, *J* = 10.6 and 5.2 Hz, 2H), 4.19 (q, *J* = 7.2 Hz, 4H), 3.94 (q, *J* = 5.2 Hz, 4H), 3.89–3.85 (m, 4H), 3.70–3.66 (m, 4H), 3.64 (td, *J* = 4.8 and 2.1 Hz, 4H), 3.62–3.58 (m, 2H), 3.55– 3.45 (m, 14H), 3.44–3.38 (m, 6H), 3.34 (ddd, *J* = 11.5, 4.6, and 2.2 Hz, 2H), 1.07 (t, *J* = 7.2 Hz, 6H). <sup>13</sup>C-NMR (150 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ : 166.2, 153.1, 153.0, 143.9, 125.6, 109.6, 109.5, 73.1, 71.4, 71.3, 71.1, 71.0, 70.9, 69.8, 69.7, 69.6, 69.1, 60.9, 14.4. One aliphatic carbon signal was overlapping/missing. MS (MALDI): *m/z* calcd for C<sub>40</sub>H<sub>58</sub>O<sub>18</sub>Na<sup>+</sup> [M+Na]<sup>+</sup>: 849.3515; found: 849.3499. mp: 121 °C (acetone).

#### Synthesis of cryptands 6.



Cryptand 6a



A suspension of the crown ether **12a** (200 mg, 0.32 mmol), tri(ethylene glycol) ditosylate **13a** (147 mg, 0.32 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (153 mg, 0.96 mmol) in DMF (15 mL) was heated at 100 °C for 16 h. After evaporation of the solvent, 10% HCl (aq.) was added to the residue and the aqueous phase was extracted with AcOEt. The organic extract was dried (MgSO<sub>4</sub>), and concentrated. The residue was purified by GPC (eluent CHCl<sub>3</sub>) to afford a white solid, which was washed with hexane (150 mg, 63%). IR (KBr,  $\nu_{max}$ ) cm<sup>-1</sup>: 2936, 1707, 1593, 1504, 1432, 1334, 1252, 1209, 1118, 1031, 769.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ: 7.20 (s, 4H), 4.31 (q, *J* = 7.1 Hz, 4H), 4.18–4.13 (m, 12H), 3.98–3.95 (m, 4H), 3.90–3.87 (m, 8H), 3.80 (s, 8H), 3.79 (s, 4H), 1.35 (t, *J* = 7.1 Hz, 6H).

<sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ: 166.1, 152.2, 142.5, 125.1, 108.3, 72.5, 71.5, 70.9, 70.8, 69.6, 69.5, 61.0, 14.3.

MS (MALDI): m/z calcd for C<sub>36</sub>H<sub>50</sub>O<sub>16</sub>Na<sup>+</sup> [M+Na]<sup>+</sup>: 761.2991; found: 761.2994. mp: 95–96 °C (EtOH).

Cryptand 6b



A suspension of the crown ether **12b** (200 mg, 0.28 mmol), tetra(ethylene glycol) ditosylate **13b** (140.7 mg, 0.28 mmol), and  $Cs_2CO_3$  (274 mg, 0.84 mmol) in DMF (15 mL) was heated at 95 °C for 20 h. After evaporation of the solvent, 10% HCl (aq.) and water were added to the residue and the aqueous phase was extracted with AcOEt. The organic extract was dried (MgSO<sub>4</sub>), and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH, 10:1) to afford a crude product, which was recrystalized from EtOH (colorless solid, 141 mg, 58%).

IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 2931, 2871, 1715, 1587, 1505, 1430, 1336, 1240, 1213, 1128, 1034.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ: 7.22 (s, 4H), 4.33 (q, *J* = 7.1 Hz, 4H), 4.23–4.19 (m, 4H), 4.17–4.13 (m, 8H), 3.88–3.84 (m, 12H), 3.76–3.65 (m, 24H), 1.36 (t, *J* = 7.1 Hz, 6H).

<sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ: 166.1, 152.2, 142.5, 125.1, 108.6, 72.5, 71.1, 70.9, 70.8, 70.63, 70.59, 69.6, 69.0, 61.0, 14.4.

MS (MALDI): m/z calcd for C<sub>42</sub>H<sub>62</sub>O<sub>19</sub>Na<sup>+</sup> [M+Na]<sup>+</sup>: 893.3778; found: 893.3775. mp: 93–94 °C (EtOH).

Method C



## Compound 14



A suspension of ethyl gallate (5) (0.512 g, 2.58 mmol), tri(ethylene glycol) monotosylate (3.27 g, 10.1 mmol), K<sub>2</sub>CO<sub>3</sub> (1.75 g, 12.7 mmol) in DMF (15 mL) and 1,2-dichlorobenzene (3.0 mL) was heated at 90 °C for 20 h. After evaporation of the solvent, 10% HCl (aq.) was added to the residue and the aqueous phase was extracted with AcOEt and CH<sub>2</sub>Cl<sub>2</sub>. The organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; toluene/AcOEt, 2:1) to afford a pale yellow oil (1.21 g, 78%).

IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 2873, 1714, 1586, 1499, 1429, 1368, 1332, 1299, 1213, 1120, 1032.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.30 (s, 2H), 4.35 (q, J = 7.1 Hz, 2H), 4.25–4.19 (m, 6H), 3.90–3.87

(m, 4H), 3.84–3.80 (m, 2H), 3.78–3.65 (m, 18H), 3.65–3.61 (m, 6H), 1.38 (t, *J* = 7.1 Hz, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 165.9, 152.1, 142.2, 125.2, 108.7, 72.2, 71.21, 71.18, 70.6, 70.5, 70.4,

69.5, 68.7, 60.9, 42.6, 14.2. Three aliphatic carbon signals were overlapping/missing.

MS (MALDI): m/z calcd for C<sub>27</sub>H<sub>43</sub>Cl<sub>3</sub>O<sub>11</sub>Na<sup>+</sup> [M+Na]<sup>+</sup>: 671.1763; found: 671.1733.

### Compound 15a

A suspension of ethyl gallate (0.513 g, 2.52 mmol), tri(ethylene glycol) monotosylate (3.07 g, 10.1 mmol), K<sub>2</sub>CO<sub>3</sub> (1.74 g, 12.6 mmol) in DMF (15 mL) was heated at 90 °C for 19 h. After evaporation of the solvent, 10% HCl (aq.) was added to the residue and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; acetone/AcOEt, 2:1) to afford a pale yellow oil (0.832 g, 64%). IR (KBr,  $v_{max}$ ) cm<sup>-1</sup>: 3421, 2874, 1713, 1587, 1499, 1430, 1368, 1332, 1244, 1214, 1121, 938, 888, 767.

EtO<sub>2</sub>C

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.30 (s, 2H), 4.35 (q, *J* = 7.1 Hz, 2H), 4.29–4.25 (m, 2H), 4.24–4.20 (m, 4H), 3.92–3.84 (m, 6H), 3.77–3.64 (m, 18H), 3.62–3.57 (m, 6H), 1.38 (t, *J* = 7.1 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 166.1, 152.1, 142.2, 125.4, 108.8, 72.8, 72.7, 72.5, 70.8, 70.6, 70.5,

70.4, 69.6, 68.7, 61.7, 61.6, 61.1, 14.4. One aliphatic carbon signal was overlapping/missing. MS (MALDI): m/z calcd for C<sub>27</sub>H<sub>46</sub>O<sub>14</sub>Na<sup>+</sup> [M+Na]<sup>+</sup>: 617.2780; found: 617.2768.

#### Compound 4a



15a

Et<sub>3</sub>N (3.15 mL, 22.6 mmol) was added to a solution of triol **15a** (2.56 g, 5.02 mmol), *p*-toluenesulfonyl chloride (3.36 g, 17.6 mmol), and DMAP (0.179 g, 1.46 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30.0 mL) under ice bath, then the mixture was stirred for 90 min at room temperature. The mixture was neutralized with dil. HCl (aq), and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to give a residue, which was chromatographed (SiO<sub>2</sub>; hexane/AcOEt, 1:2) to give a pale yellow oil (3.25 g, 67%).

IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 2874, 1713, 1597, 1497, 1429, 1356, 1333, 1213, 1189, 1176, 1121, 1019, 923, 818, 769, 664.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.81–7.76 (m, 6H), 7.36–7.31 (m, 6H), 7.29 (s, 2H), 4.35 (q, *J* = 7.1 Hz, 2H), 4.21–4.12 (m, 12H), 3.85–3.81 (m, 4H), 3.78–3.75 (m, 2H), 3.71–3.63 (m, 12H), 3.62–3.56 (m, 6H), 2.43 (s, 9H), 1.38 (t, *J* = 7.1 Hz, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 166.0, 152.1, 144.8, 142.3, 132.8, 129.8, 127.8, 125.3, 108.8, 72.3, 70.7, 70.6, 70.5, 70.3, 69.6, 69.24, 69.20, 68.7, 68.61, 68.58, 61.0, 21.5, 14.3. Four aromatic carbon signals were overlapping/missing. Two aliphatic carbon signals were overlapping/missing.

MS (MALDI): m/z calcd for C<sub>48</sub>H<sub>64</sub>O<sub>20</sub>S<sub>3</sub>Na<sup>+</sup> [M+Na]<sup>+</sup>: 1079.3045; found: 1079.3037.

Compound 15b

A suspension of ethyl gallate (5) (0.714 g, 3.60 mmol), tetra (ethylene glycol) monotosylate (5.00 g, 14.4 mmol), K<sub>2</sub>CO<sub>3</sub> (2.50 g, 18.1 mmol) in DMF (25 mL) was heated at 90 °C for 20 h. After evaporation of the solvent, 10% HCl (aq.) was added to the residue and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH, 20:1) to afford a pale yellow oil (1.57 g, 60%).

IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 3446, 2873, 1713, 1587, 1499, 1430, 1332, 1245, 1214, 1119, 945, 768.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.30 (s, 2H), 4.35 (q, *J* = 7.2 Hz, 2H), 4.26–4.19 (m, 6H), 3.90–3.86 (m, 4H), 3.84–3.80 (m, 2H), 3.76–3.69 (m, 12H), 3.69–3.64 (m, 18H), 3.61–3.57 (m, 6H), 3.35–2.70 (m, 3H), 1.38 (t, *J* = 7.2 Hz, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 166.0, 152.1, 142.2, 125.2, 108.7, 72.6, 72.5, 72.4, 70.7, 70.5, 70.3, 70.2, 69.5, 68.7, 61.5, 61.0, 14.3. Six aliphatic carbon signals were overlapping/missing.
MS (MALDI): *m/z* calcd for C<sub>33</sub>H<sub>58</sub>O<sub>17</sub>Na<sup>+</sup> [M+Na]<sup>+</sup>: 749.3566 ; found: 749.3571.

#### Compound 4b



Tritosylate **4b** (0.467 g, 0.600 mmol) was synthesized from the triol **15b** (0.434 g, 0.600 mmol), using the procedure described above, as a pale yellow oil (65% yield) after chromatographic purification (SiO<sub>2</sub>; haxane/AcOEt, 1:1).

IR (KBr, v<sub>max</sub>) cm<sup>-1</sup>: 2873, 1713, 1597, 1497, 1429, 1356, 1333, 1213, 1189, 1177, 1114, 1019, 923, 818, 769.

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 7.81–7.76 (m, 6H), 7.36–7.32 (m, 6H), 7.29 (s, 2H), 4.35 (q, *J* = 7.2 Hz, 2H), 4.23–4.12 (m, 12H), 3.88–3.83 (m, 4H), 3.80–3.76 (m, 2H), 3.72–3.65 (m, 12H), 3.65–3.55 (m, 18H), 1.38 (t, *J* = 7.2 Hz, 3H).

<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 165.9, 152.1, 144.8, 142.3, 132.8, 129.8, 127.8, 125.3, 108.8, 72.3, 70.7, 70.6, 70.5, 70.3, 69.6, 69.23, 69.20, 68.7, 68.61, 68.58, 61.0, 21.5, 14.3. Four aromatic and six aliphatic carbon and signals were overlapping/missing.

MS (MALDI): *m*/*z* calcd for C<sub>54</sub>H<sub>76</sub>O<sub>23</sub>S<sub>3</sub>Na<sup>+</sup> [M+Na]<sup>+</sup>: 1211.3832; found: 1211.3805.

Cryptands 1a and 6a



#### Using K<sub>2</sub>CO<sub>3</sub>

A suspension of the tritosylate **4a** (152 mg, 0.156 mmol), ethyl gallate (31.3 mg, 0.158 mmol), and K<sub>2</sub>CO<sub>3</sub> (102 mg, 0.734 mmol) in DMF (7.7 mL) was heated at 100 °C for 23 h. After evaporation of the solvent, 10% HCl (aq.) was added to the residue and the aqueous phase was extracted with AcOEt and CH<sub>2</sub>Cl<sub>2</sub>. Combined organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH, 10:1) and GPC (CHCl<sub>3</sub>) to afford a mixture of two cryptands **1a** and **6a**, which was separated by HPLC (0.5 mM solution of Na<sub>2</sub>HPO<sub>4</sub> and NaH<sub>2</sub>PO<sub>4</sub>/acetonitrile/MeOH, 9:5:5, first peak: cryptand **1a**, second peak: cryptand **6a**). Each cryptand was purified by column chromatography (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH, 10:1) to remove the salts to give the cross-chain bridging cryptand **1a** (19.7 mg, 17%) as a white solid and linear cryptand **6a** (16.6 mg 15%) as a white solid, respectively.

<HPLC conditions>

Column: GL Siences Inertsil ODS-3, 5  $\mu$ m (10 × 250 mm)

Eluent: buffer solution/acetonitrile/MeOH = 5/9/5 [v/v/v] (buffer solution, aqueous 1 mM sodium dihydrogen phosphate:1 mM disodium hydrogen phosphate = 1:1) Flow rate: 2.0 mL/min

Wavelength: 254 nm

# Using Cs<sub>2</sub>CO<sub>3</sub>

The cross-chain bridging cryptand **1a** (17.2 mg, 15%) and the linear cryptand **6a** (11.2 mg 10%) were synthesized from the tritosylate **4a** (152 mg, 0.156 mmol), ethyl gallate (30.9 mg, 0.156 mmol), and cesium carbonate (0.228 g, 0.698 mmol).

Cryptands 1b and 6b



## Using K<sub>2</sub>CO<sub>3</sub>

A suspension of the tritosylate **4b** (152 mg, 0.128 mmol), ethyl gallate (25.5 mg, 0.129 mmol), and  $K_2CO_3$  (80.5 mg, 0.582 mmol) in DMF (7.7 mL) was heated at 100 °C for 22 h. After evaporation of the solvent, 10% HCl (aq.) was added to the residue and the aqueous phase was extracted with AcOEt and CH<sub>2</sub>Cl<sub>2</sub>. Combined organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH, 10:1) and GPC (CHCl<sub>3</sub>) to afford a mixture of two

cryptands **1b** and **6b**, which was separated by HPLC (1.0 mM solution of Na<sub>2</sub>HPO<sub>4</sub> and NaH<sub>2</sub>PO<sub>4</sub>/acetonitrile/MeOH, 6:11:5, first peak: cryptand **6b**, second peak: cryptand **1b**). Each cryptand was purified by column chromatography (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH, 10:1) to remove the salts to give the cross-chain bridging cryptand **1b** (19.7 mg, 17%) as a white solid and linear cryptand **6b** (15.1 mg 13%) as a white solid, respectively. <HPLC conditions> Column: GL Siences Inertsil ODS-3, 5  $\mu$ m (10 × 250 mm) Eluent: buffer solution/acetonitrile/MeOH = 6/11/5 [*v/v/v*] (buffer solution, aqueous 1 mM sodium dihydrogen phosphate:1 mM disodium hydrogen phosphate = 1:1)

Flow rate: 3.0 mL/min

Wavelength: 254 nm

## Using Cs<sub>2</sub>CO<sub>3</sub>

The cross-chain bridging cryptand **1b** (16.6 mg, 15%) and the linear cryptand **6b** (10.8 mg 9%) were obtained from the tritosylate **4a** (156 mg, 0.131 mmol), ethyl gallate (26.2 mg, 0.132 mmol), and cesium carbonate (0.196 g, 0.602 mmol), as described above.



Figure S1. Interconversion of the cross-chain bridging cryptand 1b between both enantiomers.



**Figure S2.** Recycle GPC analysis of the linking reaction of the crown ether **3a** using (a) Na<sub>2</sub>CO<sub>3</sub>, (b) K<sub>2</sub>CO<sub>3</sub>, and (c) Cs<sub>2</sub>CO<sub>3</sub> as bases.



**Figure S3.** Recycle GPC analysis of the linking reaction of the crown ether **3b** using (a) Li<sub>2</sub>CO<sub>3</sub>, (b) Na<sub>2</sub>CO<sub>3</sub>, (c) K<sub>2</sub>CO<sub>3</sub>, and (d) Cs<sub>2</sub>CO<sub>3</sub> as bases.



Figure S4. <sup>1</sup>H NMR spectrum (600 MHz,  $C_6D_6$ ) of the cryptand 1c.



Figure S5. <sup>13</sup>C NMR spectra (150 MHz, C<sub>6</sub>D<sub>6</sub>) of the cryptand 1c.





Figure S6. COSY spectrum (600 MHz,  $C_6D_6$ ) of the cryptand 1c.



Figure S7. ROESY spectrum (600 MHz, C<sub>6</sub>D<sub>6</sub>) of the cryptand 1c.



Figure S8. HSQC spectrum (600 MHz,  $C_6D_6$ ) of the cryptand 1c.





Figure S9. HMBC spectrum (600 MHz,  $C_6D_6$ ) of the cryptand 1c.



**Figure S10.** Mass spectrum (MALDI) of the cryptand **1c**: experimental (top) and calculated (bottom) isotopic patterns.



Figure S11. <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of the linear cryptand 6a.





Figure S12. COSY spectrum (600 MHz, CDCl<sub>3</sub>) of the linear cryptand 6a.



Figure S13. ROESY spectrum (600 MHz, CDCl<sub>3</sub>) of the linear cryptand 6a.



Figure S14. Mass spectrum of the cryptand 6a: experimental (top) and calculated (bottom) isotopic patterns.



Figure S15. <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of the cryptand 6b.





Figure S16. COSY spectrum (600 MHz, CDCl<sub>3</sub>) of the linear cryptand 6b.



Figure S17. ROESY spectrum (600 MHz, CDCl<sub>3</sub>) of the linear cryptand 6b.



Figure S18. Mass spectrum of the cryptand 6b: experimental (top) and calculated (bottom) isotopic patterns.



**Figure S19.** Detailed minor processes of the triple linking reaction between the minor phenoxide ion of ethyl gallate in the first step and the tosylate **4**.

#### **Minor process**

In the first linking step, the minor phenoxide anion might statistically attack to tosyloxy alkyl groups at 3- and 4-positions in 4 to afford a 2:1 mixture of intermediates  $\mathbf{F}$  and  $\mathbf{G}$ . 4-Hydroxy group of the intermediates  $\mathbf{F}$  and  $\mathbf{G}$  dominantly deprotonated because of electron-withdrawing effect of ethoxy carbonyl group. The second intramolecular linking of the intermediate  $\mathbf{F}$  might give the crown ethers  $\mathbf{H}$  ( $\mathbf{E}$  in the Figure 4) and  $\mathbf{I}$  ( $\mathbf{D}$  in the Figure 4). In this step, the major phenoxide anion of  $\mathbf{F}$  might predominantly attack to tosyloxy alkyl group at 4-position. Because alkyl chain of 4-position should inhibit the cross-linkage giving intermediate  $\mathbf{I}$  ( $\mathbf{D}$  in the Figure 4). Finally, crown ethers  $\mathbf{H}$  ( $\mathbf{E}$  in the Figure 4) and  $\mathbf{I}$  ( $\mathbf{D}$  in the Figure 4) are converted to the linear and cross-chain bridging cryptands 6 and 1, respectively. In contrast, cross-chain bridging 1 should be mainly obtained by the second and third intramolecular linking of the intermediate  $\mathbf{G}$  via intermediate  $\mathbf{J}$  ( $\mathbf{C}$  in the Figure 4). Therefore, this minor process gave linear cryptand 6 as a major product, totally, triple linking reaction may furnish a less than 2:1 mixture of the cross-chain bridging and linear cryptands 1 and 6.



The relationship between flow rate and each area of each enantiomer and the middle of the enantiomers of **1c**.

Flow rate	Average of	Area of left	Area of center	Area of right	Non-
(mL/min)	retention time (s)	peak (%)	(%)	peak (%)	racemate (%)
0.4	922	32.6	34.0	33.3	66.0
0.6	607	38.0	22.5	39.5	77.5
0.8	448	40.6	17.0	42.4	83.0
1.0	357	42.4	13.2	44.4	86.8
1.2	296	43.1	12.1	44.8	87.9

Figure S20. Flow rate-dependent chiral HPLC analysis of the cryptand 1c using CHIRALPAK IG-3 (4.6 mml.D.  $\times$  25 cmL) as a stationary phase. Flow rate: 0.4–1.2 mL/min, eluent: AcOEt/Et<sub>3</sub>N (100:0.5), detection: 254 nm, temp.: rt.



**Figure S21.** X-ray crystal structure of the racemic cryptand **1a**: (a) a crystal lattice, and (b) *c*-axis projection. Gray: carbon; red: oxygen.

Parameter	(±)-1a		
Formula	$C_{36}H_{50}O_{16}$		
Formula weight	738.78		
Temperature	−100 °C		
Crystal color, habit	Colorless, platelet		
Crystal size / mm	$0.600\times0.200\times0.080$		
Crystal system	Triclinic		
Space group	P-1 (#2)		
<i>a</i> / Å	8.5825(5)		
<i>b</i> / Å	14.5897(9)		
<i>c</i> / Å	16.1070(10)		
$\alpha$ / deg	68.243(5)		
eta / deg	83.475(6)		
γ / deg	79.053(6)		
$V/\text{\AA}^3$	1837.0(2)		
Ζ	2		
$D_{ m calcd}$ / g cm <sup>-3</sup>	1.336		
<i>F</i> (000)	788.00		
$2\theta_{\rm max}$ / deg	54.9		
No. of reflns meads	36508		
No. of obsd reflns	8379		
No. of variables	488		
$R_1 \left[I > 2\sigma(I)\right]^a$	0.0550		
$wR_2$ (all reflns) <sup>b</sup>	0.1153		
Goodness of fit	1.022		
${}^{a}R_{1} = \Sigma \left(  F_{o}  -  F_{c}  \right) / \Sigma \left(  $	$F_{\rm o} $ ). ${}^{b}wR_{2} = \{ \sum [w(F_{\rm o}^{2} - F_{\rm c}^{2})^{2}] / \sum w(F_{\rm o}^{2})^{2} \}$		

 Table S1. Crystal data of the racemic cryptand 1a.



Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of a mixture of the crown ethers **10a** and **11a**.



Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of a mixture of the crown ethers **10a** and **11a**.



Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of the crown ether **3a**.



Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the crown ether **3a**.



Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of the crown ether **12a**.



Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the crown ether **12a**.



Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of the compound **9b**.



Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the cryptand 9b.



Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of the compound **9c**.



Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the compound **9c**.



Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of a mixture of the crown ethers **10b** and **11b**.



Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of a mixture of the crown ethers **10b** and **11b**.



Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of the crown ether **3b**.



Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the crown ether **3b**.



Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of the crown ether **12b**.



Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the crown ether **12b**.



Figure. <sup>1</sup>H NMR (600 MHz,  $C_6D_6$ ) spectrum of the cryptand 1c.

![](_page_49_Figure_2.jpeg)

Figure. <sup>13</sup>C NMR (150 MHz,  $C_6D_6$ ) spectrum of the cryptand 1c.

![](_page_50_Figure_0.jpeg)

Figure. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) spectrum of the cryptand **6a**.

![](_page_50_Figure_2.jpeg)

Figure. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) spectrum of the cryptand **6a**.

![](_page_51_Figure_0.jpeg)

Figure. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) spectrum of the cryptand 6b.

![](_page_51_Figure_2.jpeg)

Figure. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) spectrum of the cryptand **6b**.

![](_page_52_Figure_0.jpeg)

![](_page_52_Figure_1.jpeg)

![](_page_52_Figure_2.jpeg)

Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the compound 14.

![](_page_53_Figure_0.jpeg)

Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of the compound **15a**.

![](_page_53_Figure_2.jpeg)

Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the compound 15a.

![](_page_54_Figure_0.jpeg)

![](_page_54_Figure_1.jpeg)

![](_page_54_Figure_2.jpeg)

Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the compound 4a.

![](_page_55_Figure_0.jpeg)

Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of the compound **15b**.

![](_page_55_Figure_2.jpeg)

Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the compound **15b**.

![](_page_56_Figure_0.jpeg)

Figure. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) spectrum of the compound 4b.

![](_page_56_Figure_2.jpeg)

Figure. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) spectrum of the compound 4b.